Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau”
The first-line therapy of metastatic renal cell carcinoma (mRCC) has revolutionized with the approval of immune checkpoint inhibitors (ICIs) in combination with or without tyrosine kinase inhibitors (TKIs). The choice among the many different immuno-combinations (ICI-ICI or ICI-TKI) is challenging d...
Saved in:
| Main Authors: | Sara Elena Rebuzzi, Giuseppe Fornarini, Alessio Signori, Pasquale Rescigno, Giuseppe Luigi Banna, Sebastiano Buti |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2351669 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
HDAC6 inhibition by ITF3756 modulates PD-L1 expression and monocyte phenotype: insights for a promising immune checkpoint blockade co-treatment therapy
by: Valeria Spadotto, et al.
Published: (2025-05-01) -
Correction: HDAC6 inhibition by ITF3756 modulates PD-L1 expression and monocyte phenotype: insights for a promising immune checkpoint blockade co-treatment therapy
by: Valeria Spadotto, et al.
Published: (2025-08-01) -
Multifunctional Biomimetic Nanocarriers for Dual‐Targeted Immuno‐Gene Therapy Against Hepatocellular Carcinoma
by: Yupeng Sun, et al.
Published: (2024-09-01) -
The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab
by: Giulia Claire Giudice, et al.
Published: (2025-01-01) -
Reporting of immune-related adverse events in US Food and Drug Administration approvals of immune checkpoint inhibitors
by: Shaili Tapiavala, et al.
Published: (2025-08-01)